Genetic Signatures Limited (ASX: GSS) informed the market on 17 September 2026 that it has received a Section 249D notice from BCAL Diagnostics Limited. Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary 3base® platform technology. The company designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products, marketed under the EasyScreen™ brand, for the routine detection of infectious diseases. This announcement was made in accordance with ASX Listing Rule 3.17A, which mandates disclosure of such requests.
The notice from BCAL Diagnostics Limited constitutes a formal request for the directors of GSS to call and arrange a general meeting of shareholders. The explicit purpose of this requested meeting is to consider and potentially pass a resolution concerning the composition of the company’s board. Specifically, the proposed resolution states: “That Jenny Harry be removed as director of the Company immediately following the passing of this resolution.”
In response to the Section 249D notice, Genetic Signatures Limited confirmed it is actively reviewing the validity of the request. The company emphasised its commitment to comply with its obligations under the Corporations Act. Should GSS determine the notice to be valid and in due form, it will proceed with the necessary administrative steps to convene a general meeting for its shareholders as required by law, to put the proposed resolution to a vote.
